公开(公告)号：EP3007702A1

公开(公告)日：2016-04-20

申请号：EP14811288.1

申请日：2014-05-27

申请人： Dong-A ST Co., Ltd.

发明人： KIM, Soon-Hoe ,  SON, Mi-Won ,  JANG, Sun-Woo ,  PARK, Chan-Woong ,  MA, Kyung-Wan ,  JUNG, Sang-Won

IPC分类号： A61K31/54 ,  A61K31/728 ,  A61P19/02 ,  A61P19/00

CPC分类号： A61K31/728 ,  A61K9/0019 ,  A61K31/5415 ,  A61K47/02 ,  A61K2300/00

摘要： The present invention relates to the pharmaceutical composition for the treatment of osteoarthritis comprising piroxicam or pharmaceutically acceptable salt thereof and hyaluronic acid or pharmaceutically acceptable salt thereof at a specific ratio that generates synergistic effect on both anti-inflammatory and analgesic effects simultaneously. The present invention provides a pharmaceutical composition for the treatment of osteoarthritis comprising 0.25-10.0 wt% of piroxicam or its pharmaceutically acceptable salt and 0.5-5.0 wt% of hyaluronic acid or its pharmaceutically acceptable salt, where the weight ratio between piroxicam or its pharmaceutically acceptable salt and hyaluronic acid or its pharmaceutically acceptable salt is between 1:1 and 1:3. The liquid pharmaceutical composition according to the present invention has an outstanding therapeutic effect simultaneously on both inflammation and pain, thus providing an injectable formulation for intra-articular injection with synergistic effect on the treatment of osteoarthritis.

摘要翻译： 提供了一种用于治疗骨关节炎的以特定的比例含有炎痛喜康或其药学上可接受的盐和透明质酸或其药学上可接受的盐的药物组合物。 该组合物基因率上同时在两个抗炎和镇痛作用的协同效果。 药物组合物含有炎痛喜康或其药学上可接受的盐和透明质酸或其药学上可接受的盐的0.5-5.0％（重量）的0.25-10.0％（重量），吡罗昔康worin或其药学上可接受的盐和透明质酸或其药学上可接受的盐之间的重量比 为1：1和1：3。

公开(公告)号：EP2822561A1

公开(公告)日：2015-01-14

申请号：EP13758220.1

申请日：2013-03-07

申请人： Dong-A ST Co., Ltd.

发明人： KIM, Soon-Hoe ,  SON, Mi-Won ,  JANG, Sun-Woo ,  KANG, Myung-Joo ,  MA, Kyung-Wan

IPC分类号： A61K31/54 ,  A61K31/728 ,  A61P29/00 ,  A61P25/00

CPC分类号： A61K47/40 ,  A61K9/0019 ,  A61K31/5415 ,  A61K31/728 ,  A61K47/10 ,  A61K2300/00

摘要： The present invention relates to a novel liquid composition comprised of piroxicam or its pharmaceutically acceptable salt (a non-steroid anti-inflammatory drug) and hyaluronic acid or its pharmaceutically acceptable salt (used for treatment of degenerative arthritis). Specifically, the invention provides a highly physicochemically stable liquid injection, comprising piroxicam and hyaluronic acid as active ingredients and β-cyclodextrin or its derivative and polyethylene glycol as additives to enhance its physicochemical stability, and the preparation method thereof. Therefore, the novel composition and the formulation method thereof provided by the present invention may be used to produce a liquid injection composition of piroxicam and hyaluronic acid.

摘要翻译： 本发明涉及由吡罗昔康或其药学上可接受的盐（非类固醇抗炎药）和透明质酸或其药学上可接受的盐（用于治疗退行性关节炎）组成的新型液体组合物。 具体而言，本发明提供了一种高度物理化学稳定的液体注射剂及其制备方法，所述液体注射剂包含吡罗昔康和透明质酸作为活性成分并且β-环糊精或其衍生物和聚乙二醇作为添加剂以增强其物理化学稳定性。 因此，本发明提供的新型组合物及其制剂方法可用于制备吡罗昔康和透明质酸的液体注射组合物。